Addgene: LRG2.1 Citations

LRG2.1 Citations (34)

Originally described in: LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia.
Tarumoto Y, Lu B, Somerville TDD, Huang YH, Milazzo JP, Wu XS, Klingbeil O, El Demerdash O, Shi J, Vakoc CR Mol Cell. 2018 Feb 28. pii: S1097-2765(18)30109-6. doi: 10.1016/j.molcel.2018.02.011. PubMed Journal

Articles Citing LRG2.1

Showing 1 to 10 of 34 entries

Show entries

Search table:

Articles
CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy. Qin M, Deng C, Wen L, Luo G, Meng Y. J Transl Med. 2024 May 30;22(1):516. doi: 10.1186/s12967-024-05235-2. PubMed
Genetic dependencies associated with transcription factor activities in human cancer cell lines. Thatikonda V, Supper V, Wachter J, Kaya O, Kombara A, Bilgilier C, Ravichandran MC, Lipp JJ, Sharma R, Badertscher L, Boghossian AS, Rees MG, Ronan MM, Roth JA, Grosche S, Neumuller RA, Mair B, Mauri F, Popa A. Cell Rep. 2024 May 28;43(5):114175. doi: 10.1016/j.celrep.2024.114175. Epub 2024 Apr 30. PubMed
IkappaBzeta is a dual-use coactivator of NF-kappaB and POU transcription factors. Alpsoy A, Wu XS, Pal S, Klingbeil O, Kumar P, El Demerdash O, Nalbant B, Vakoc CR. Mol Cell. 2024 Mar 21;84(6):1149-1157.e7. doi: 10.1016/j.molcel.2024.01.007. Epub 2024 Feb 2. PubMed
Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR. Zong D, Koussa NC, Cornwell JA, Pankajam AV, Kruhlak MJ, Wong N, Chari R, Cappell SD, Nussenzweig A. Genes Dev. 2023 Oct 1;37(19-20):913-928. doi: 10.1101/gad.351085.123. Epub 2023 Nov 6. PubMed
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy. Kim IK, Diamond M, Yuan S, Kemp S, Li Q, Lin J, Li J, Norgard R, Thomas S, Merolle M, Katsuda T, Tobias J, Politi K, Vonderheide R, Stanger B. Res Sq. 2023 Jun 1:rs.3.rs-2960521. doi: 10.21203/rs.3.rs-2960521/v1. Preprint. PubMed
A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy. Chen W, Ma C, Wang H, Liu L, Tong J, Witkowski M, Aifantis I, Ghassemi S. Res Sq. 2023 Apr 21:rs.3.rs-2762929. doi: 10.21203/rs.3.rs-2762929/v1. Preprint. PubMed
Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance. Li F, Wang Y, Hwang I, Jang JY, Xu L, Deng Z, Yu EY, Cai Y, Wu C, Han Z, Huang YH, Huang X, Zhang L, Yao J, Lue NF, Lieberman PM, Ying H, Paik J, Zheng H. bioRxiv. 2023 Feb 11:2023.02.10.528023. doi: 10.1101/2023.02.10.528023. Preprint. PubMed
ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation. Gao Y, He XY, Wu XS, Huang YH, Toneyan S, Ha T, Ipsaro JJ, Koo PK, Joshua-Tor L, Bailey KM, Egeblad M, Vakoc CR. Nat Cell Biol. 2023 Feb;25(2):298-308. doi: 10.1038/s41556-022-01060-1. Epub 2023 Jan 19. PubMed
PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA. Breast Cancer Res. 2023 Jan 3;25(1):1. doi: 10.1186/s13058-022-01559-3. PubMed
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. Sun X, Klingbeil O, Lu B, Wu C, Ballon C, Ouyang M, Wu XS, Jin Y, Hwangbo Y, Huang YH, Somerville TDD, Chang K, Park J, Chung T, Lyons SK, Shi J, Vogel H, Schulder M, Vakoc CR, Mills AA. Nature. 2023 Jan;613(7942):195-202. doi: 10.1038/s41586-022-05551-x. Epub 2022 Dec 21. PubMed

If you have published an article using this material, please email us at help@addgene.org to have your article added to this page.